Improved PFS and OS With Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs Placebo-Rd in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Final Data From the Phase 3 China Continuation of TOURMALINE-MM1

被引：0
|
作者：
Hou, Jian [1 ]
Jin, Jie [2 ]
Xu, Yan [3 ]
Wu, Depei [4 ]
Ke, Xiaoyan [5 ]
Daobin, Zhou [6 ]
Lu, Jin [7 ]
Du, Xin [8 ]
Chen, Xiequn [9 ]
Li, Junmin [10 ]
Liu, Jing [11 ]
Gupta, Neeraj [12 ]
Hanley, Michael [12 ]
Li, Hongmei [12 ]
Hua, Zhaowei [12 ]
Wang, Bingxia [12 ]
Zhang, Xiaoquan [12 ]
Wang, Hui [12 ]
van de Velde, Helgi [12 ]
Richardson, Paul [13 ]
Moreau, Philippe [14 ]
机构：
[1] Second Mil Med Univ, ChangZheng Hosp, Shanghai, Peoples R China
[2] Zhe Jiang Med Univ, Hosp Affiliated 1, Hangzhou, Zhejiang, Peoples R China
[3] Chinese Acad Med Sci, Inst Hematol & Blood Dis, Tianjin, Peoples R China
[4] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
[5] Beijing Med Univ, Affiliated Hosp 3, Beijing, Peoples R China
[6] Peking Univ, Med Coll Hosp, Beijing, Peoples R China
[7] Peking Univ, Peoples Hosp, Beijing, Peoples R China
[8] Guangdong Prov Peoples Hosp, Guangzhou, Guangdong, Peoples R China
[9] Fourth Mil Med Univ, Xijing Hosp, Xian, Peoples R China
[10] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai, Peoples R China
[11] Hosp Xiang Ya Med Univ, Hosp 3, Changsha, Hunan, Peoples R China
[12] Millennium Pharmaceut Inc, Cambridge, MA USA
[13] Dana Farber Canc Inst, Boston, MA 02115 USA
[14] CHU Nantes, Univ Hosp Hotel Dieu HME, Nantes, France
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷 / 01期
关键词：
D O I：
10.1016/j.clml.2017.03.121
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS-119
引用
收藏
页码：E67 / E67
页数：1
相关论文
共 50 条
  • [21] Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
    Hou, Jian
    Jin, Jie
    Xu, Yan
    Wu, Depei
    Ke, Xiaoyan
    Zhou, Daobin
    Lu, Jin
    Du, Xin
    Chen, Xiequn
    Li, Junmin
    Liu, Jing
    Gupta, Neeraj
    Hanley, Michael J.
    Li, Hongmei
    Hua, Zhaowei
    Wang, Bingxia
    Zhang, Xiaoquan
    Wang, Hui
    van de Velde, Helgi
    Richardson, Paul G.
    Moreau, Philippe
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
  • [22] Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
    Jian Hou
    Jie Jin
    Yan Xu
    Depei Wu
    Xiaoyan Ke
    Daobin Zhou
    Jin Lu
    Xin Du
    Xiequn Chen
    Junmin Li
    Jing Liu
    Neeraj Gupta
    Michael J. Hanley
    Hongmei Li
    Zhaowei Hua
    Bingxia Wang
    Xiaoquan Zhang
    Hui Wang
    Helgi van de Velde
    Paul G. Richardson
    Philippe Moreau
    [J]. Journal of Hematology & Oncology, 10
  • [23] Ixazomib plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (RRMM) patients in real-world experience: a pooled analysis from the INSIGHT MM observational study and the Czech Registry of Monoclonal Gammopathies (RMG)
    Weisel, K.
    Hajek, R.
    Terpos, E.
    Lee, H. C.
    Chari, A.
    Costello, C. L.
    Puig, N.
    Leleu, X.
    Berdeja, J. G.
    Davies, F. E.
    Usmani, S. Z.
    Hungria, V. T. M.
    Boccadoro, M.
    Rifkin, R. M.
    Zonder, J. A.
    Cook, G.
    Brozova, L.
    Barinova, M.
    Ren, K.
    Skacel, T.
    Stull, D. M.
    Maisnar, V.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 125 - 125
  • [24] Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
    Leleu, Xavier
    Masszi, Tamas
    Bahlis, Nizar J.
    Viterbo, Luisa
    Baker, Bartrum
    Gimsing, Peter
    Maisnar, Vladimir
    Samoilova, Olga
    Rosinol, Laura
    Langer, Christian
    Song, Kevin
    Izumi, Tohru
    Cleeland, Charles
    Berg, Deborah
    Lin, Huamao Mark
    Zhu, Yanyan
    Skacel, Tomas
    Moreau, Philippe
    Richardson, Paul G.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (08) : 985 - 993
  • [25] PHASE 1 PHARMACOKINETIC (PK) STUDY OF IXAZOMIB CITRATE (MLN9708) PLUS LENALIDOMIDE AND DEXAMETHASONE IN ASIAN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Gupta, N.
    Goh, Y. T.
    Min, C. K.
    Lee, J. H.
    Suh, C.
    Kim, K.
    Wong, R.
    Chim, J.
    Hanley, M. J.
    Yang, H.
    Venkatakrishnan, K.
    Hui, A. M.
    Schusterbauer, C.
    Chng, W. J.
    [J]. HAEMATOLOGICA, 2014, 99 : 372 - 372
  • [26] Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial
    Stewart, A. Keith
    Siegel, David
    Ludwig, Heinz
    Facon, Thierry
    Goldschmidt, Hartmut
    Jakubowiak, Andrzej J.
    Miguel, Jesus F. San
    Obreja, Mihaela
    Blaedel, Julie
    Dimopoulos, Meletios A.
    [J]. BLOOD, 2017, 130
  • [27] Ixazomib plus Lenalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: A Pooled Analysis from the INSIGHT MM Observational Study and the Czech Registry of Monoclonal Gammopathies
    Cook, G.
    Hajek, R.
    Terpos, E.
    Lee, H. C.
    Chari, A.
    Costello, C. L.
    Puig, N.
    Leleu, X.
    Berdeja, J. G.
    Davies, F. E.
    Weisel, K. C.
    Usmani, S. Z.
    Hungria, V. T. M.
    Boccadoro, M.
    Rifkin, R. M.
    Zonder, J. A.
    Brozova, L.
    Barinova, M.
    Ren, K.
    Cacioppo, R.
    Skacel, T.
    Stull, D. M.
    Maisnar, V.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 16 - 17
  • [28] Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pboRd) in the Phase 3 TOURMALINE-MM2 Trial
    Richardson, Paul G.
    Facon, Thierry
    Venner, Christopher P.
    Bahlis, Nizar J.
    Offner, Fritz
    White, Darrell
    Karlin, Lionel
    Benboubker, Lotfi
    Rigaudeau, Sophie
    Voog, Eric
    Yoon, Sung-Soo
    Suzuki, Kenshi
    Shibayama, Hirohiko
    Zhang, Xiaoquan
    Kumar, Arun
    Twumasi-Ankrah, Philip
    Labotka, Richard
    Rifkin, Robert M.
    Lonial, Sagar
    Kumar, Shaji
    Rajkumar, S. Vincent
    Moreau, Philippe
    [J]. BLOOD, 2021, 138
  • [29] Addition of Ixazomib to an Rd Backbone Improves Clinical Benefit in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Non-Canonical NF-KB Activation-Results from the Tourmaline-MM1 Study
    Dash, Ajeeta B.
    Zhang, Jacob
    Shen, Lei
    Li, Bin
    Berg, Deborah
    Lin, Jianchang
    Avet-Loiseau, Herve
    Bahlis, Nizar
    Moreau, Philippe
    Richardson, Paul
    Di Bacco, Alessandra
    [J]. BLOOD, 2018, 132
  • [30] The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice
    Leleu, Xavier
    Boccadoro, Mario
    Lee, Hans C.
    Zonder, Jeffrey A.
    Macro, Magaret
    Ramasamy, Karthik
    Hulin, Cyrille
    Silar, Jiri
    Kuhn, Matyas
    Ren, Kaili
    Bent-Ennakhil, Nawal
    Bouillie, Sylvie
    Cherepanov, Dasha
    Stull, Dawn Marie
    Terpos, Evangelos
    [J]. BLOOD, 2021, 138
12345